Literature DB >> 17973960

Twenty-year experience with heart transplantation for infants and children with restrictive cardiomyopathy: 1986-2006.

A J Bograd1, S Mital, J C Schwarzenberger, R S Mosca, J M Quaegebeur, L J Addonizio, D T Hsu, J M Lamour, J M Chen.   

Abstract

Idiopathic restrictive cardiomyopathy (RCM) is a rare cardiomyopathy in children notable for severe diastolic dysfunction and progressive elevation of pulmonary vascular resistance (PVR). Traditionally, those with pulmonary vascular resistance indices (PVRI) >6 W.U. x m(2) have been precluded from heart transplantation (HTX). The clinical course of all patients transplanted for RCM between 1986 and 2006 were reviewed. Preoperative, intraoperative and postoperative variables were evaluated. A total of 23 patients underwent HTX for RCM, with a mean age of 8.8 +/- 5.6 years and a mean time from listing to HTX of 43 +/- 60 days. Preoperative and postoperative (114 +/- 40 days) PVRI were 5.9 +/- 4.4 and 2.9 +/- 1.5 W.U. x m(2), respectively. At time of most recent follow-up (mean = 5.7 +/- 4.6 years), the mean PVRI was 2.0 +/- 1.0 W.U. x m(2). Increasing preoperative mean pulmonary artery pressure (PA) pressure (p = 0.04) and PVRI > 6 W.U. x m(2) (chi(2)= 7.4, p < 0.01) were associated with the requirement of ECMO postoperatively. Neither PVRI nor mean PA pressure was associated with posttransplant mortality; 30-day and 1-year actuarial survivals were 96% and 86%, respectively. Five of the seven patients with preoperative PVRI > 6 W.U. x m(2) survived the first postoperative year. We report excellent survival for patients undergoing HTX for RCM despite the high proportion of high-risk patients.

Entities:  

Mesh:

Year:  2007        PMID: 17973960     DOI: 10.1111/j.1600-6143.2007.02027.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

Review 1.  Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies.

Authors:  Hamayak Sisakian
Journal:  World J Cardiol       Date:  2014-06-26

2.  Insights into restrictive cardiomyopathy from clinical and animal studies.

Authors:  Pierre-Yves Jean-Charles; Yue-Jin Li; Chang-Long Nan; Xu-Pei Huang
Journal:  J Geriatr Cardiol       Date:  2011-09       Impact factor: 3.327

3.  A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011.

Authors:  Maria Jesus Del Cerro; Steven Abman; Gabriel Diaz; Alexandra Heath Freudenthal; Franz Freudenthal; S Harikrishnan; Sheila G Haworth; Dunbar Ivy; Antonio A Lopes; J Usha Raj; Julio Sandoval; Kurt Stenmark; Ian Adatia
Journal:  Pulm Circ       Date:  2011       Impact factor: 3.017

4.  The relative atrial volume ratio and late gadolinium enhancement provide additive information to differentiate constrictive pericarditis from restrictive cardiomyopathy.

Authors:  Huaibing Cheng; Shihua Zhao; Shiliang Jiang; Minjie Lu; Chaowu Yan; Jian Ling; Yan Zhang; Qiong Liu; Ning Ma; Gang Yin; Renate Jerecic; Zuoxiang He
Journal:  J Cardiovasc Magn Reson       Date:  2011-02-25       Impact factor: 5.364

Review 5.  Clinical Characteristics and Treatment of Cardiomyopathies in Children.

Authors:  Jack F Price; Aamir Jeewa; Susan W Denfield
Journal:  Curr Cardiol Rev       Date:  2016

6.  Sevoflurane in an infant with dilated cardiomyopathy due to myocarditis and hypocalcaemia.

Authors:  Narendra Kumar
Journal:  Indian J Anaesth       Date:  2016-01

Review 7.  Pediatric Restrictive Cardiomyopathies.

Authors:  Raffaello Ditaranto; Angelo Giuseppe Caponetti; Valentina Ferrara; Vanda Parisi; Matteo Minnucci; Chiara Chiti; Riccardo Baldassarre; Federico Di Nicola; Simone Bonetti; Tammam Hasan; Luciano Potena; Nazzareno Galiè; Luca Ragni; Elena Biagini
Journal:  Front Pediatr       Date:  2022-01-25       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.